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Peptide presentation on MHC class I molecules (MHC-I) is central to mounting effective 
antiviral and antitumoral immune responses. The tapasin-related protein TAPBPR is an 
MHC-I peptide editor which shapes the final peptide repertoire displayed on the cell surface. 
Here, we review recent findings which further elucidate the mechanisms by which TAPBPR 
performs peptide editing on a molecular level, and how glycosylation on MHC-I influences 
the interaction with TAPBPR and the peptide loading complex. We also explore how the 
function of TAPBPR can be utilized to promote exogenous peptide loading directly onto 
plasma-membrane expressed MHC-I. This has led to the development of new assays to 
investigate TAPBPR-mediated peptide editing and uncovered translational opportunities of 
utilizing TAPBPR to treat human disease. 
  
Introduction 
MHC class I molecules (MHC-I) present fragments of the cellular proteome at the surface of 
cells for inspection by CD8+ T cells, thereby playing a crucial role in the immunosurveillance 
of intracellular infections and tumours. Peptide loading on MHC-I is modulated in the 
endoplasmic reticulum (ER) by the peptide loading complex (PLC). Within the PLC, tapasin 
bridges peptide-receptive MHC-I to the transporter associated with antigen processing (TAP), 
ensuring their proximity to the point of peptide influx in the ER [1-3], while also performing 
peptide editing to help select optimum peptide cargo [4-7] (Figure 1).  In 2002, a tapasin-
related protein termed TAPBPR was initially described [8]. The function and properties of 
TAPBPR remained undefined until its ability to interact with MHC-I was discovered [9]. 
Since then, the role of TAPBPR in the antigen presentation pathway has been extensively 
investigated, unveiling further complexities regarding how peptides are selected on MHC-I. 
 
The Ins of TAPBPR: Its natural role within an intracellular environment 
It is now apparent that TAPBPR is an intracellular chaperone for MHC-I and a component of 
the antigen processing and presentation pathway [9-11]. Below, we discuss some of the 
functions which TAPBPR performs and recent insights into the interaction between TAPBPR 
and MHC-I.   
 
Peptide Editing on MHC-I 
Structural predictions and site-directed mutagenesis experiments suggested that TAPBPR 
adopts a similar orientation on MHC-I to the one of tapasin, raising the intriguing possibility 
that it may be capable of performing peptide editing on MHC-I [12]. This hypothesis was 
supported a few years later following demonstration using in vitro assay that TAPBPR does 
indeed function as a peptide editor [13,14]. In contrast to tapasin, which requires artificial 
tethering to MHC-I or additional cofactors to facilitate peptide exchange [6,7], the luminal 
domain of TAPBPR alone is capable of modulating peptide editing on MHC-I [13,14]. 
Furthermore, alteration of TAPBPR expression in cells changes the peptide repertoire 
presented on MHC-I [13]. These discoveries established TAPBPR as a second peptide editor 
in the MHC-I antigen presentation pathway (Figure 1). While tapasin appears somewhat 
crucial for stable peptide:MHC-I presentation on the plasma membrane [5,15,16], TAPBPR 
depletion results in a more subtle phenotype on MHC-I surface expression, implicating 
TAPBPR in a fine-tuning or refining role of TAPBPR in the pathway [9,13]. The distinct 
environments within which the two peptide editors function represents one likely factor 
responsible for their differential effects on MHC-I. For example, tapasin performs peptide 
editing in a peptide-rich environment, which enables efficient peptide loading onto MHC-I. 
In contrast, peptide editing by human TAPBPR occurs more distally from the TAP 
transporters, presumably in an environment more devoid of optimal MHC-I binding peptides. 
Thus, peptide editing in the absence of incoming peptide would presumably result in a 
refining effect on the MHC-I immunopeptidome. 
 
Insights into the mechanisms of MHC-I peptide editing 
The discovery of TAPBPR provided a platform for the laboratories of David Margulies and 
Robert Tampe to independently solve the first crystal structures of MHC-I bound to a 
molecular chaperone [17,18]. Here, we only briefly touch on this insightful work as it is 
covered in depth in a complementary article by David Margulies in this issue of Current 
Opinion in Immunology [19]. Both published TAPBPR:MHC-I structures suggest that 
TAPBPR mediates peptide dissociation by sequestering the α2-1 region of MHC-I away from 
the peptide, consequently ‘flipping’ away residue Y84 of MHC-I which is involved in 
hydrogen bond formation with the C-terminus of the peptide [17,18]. This is similar to the 
mechanism previously proposed for tapasin [20]. However, one key difference in the reported 
structures was the localization of a loop of TAPBPR, composed of residues 22–36, which 
was modelled in the structure by Thomas and Tampe near the peptide binding groove of 
MHC-I, consequently suggesting its involvement in mediating peptide exchange [17].   
Our own recent biochemical exploration of the involvement of this loop region in peptide 
selection revealed that upon mutation of the K22-D35 loop, TAPBPR retained its capacity to 
bind to MHC-I, however lost its ability to facilitate efficient peptide exchange on HLA-
A*02:01, HLA-A*68:02 and H-2Kb molecules [21]. A leucine residue within the loop 
appears to be essential for promoting peptide dissociation from MHC-I that accommodate 
hydrophobic amino acids in their F pocket [21]. This work suggests that the loop region is 
crucial for TAPBPR-mediated peptide editing and peptide selection, at least for certain 
MHC-I variants. A similar, albeit shorter, loop is also present in tapasin and peptides 
comprising this sequence have recently been crystalized with MHC-I [22]. Using an NMR-
based approach, Skourgakis and colleagues have shown that TAPBPR senses peptide/MHC-I 
interactions along the entire length of the groove and proposed an allosterically driven release 
of the peptide in the presence of TAPBPR [23]. Together, these recent findings have revealed 
mechanistic insight into the processes involved in chaperone-mediated peptide editing. Since 
MHC-I are extremely polymorphic, it is important to consider that one rule might not fit all 
MHC-I, and multiple distinct mechanisms of peptide editing may be required to 
accommodate the high degree of variation in both the peptide and the MHC-I itself.  
 
  The glycan attached to MHC-I impacts its association with TAPBPR 
Given that TAPBPR apparently has a higher affinity for MHC-I than tapasin [14], and that 
both chaperones seem to reside in the ER [9], we have previously attempted to understand the 
reason for which TAPBPR does not outcompete tapasin for binding to MHC-I in a cellular 
environment [11]. There are several possible explanations for this phenomenon and 
subsequent findings from our laboratory suggest that the glycan attached to MHC-I is one 
important factor that influences the order in which MHC-I interacts with the two peptide 
editors [24]. While tapasin binds to mono-glucosylated MHC-I by virtue of its interaction 
with calreticulin and ERp57 [25-29] (Figure 1), the interaction of MHC-I with TAPBPR 
appears to occur in a glycan-independent manner [24]. This would permit TAPBPR to bind to 
MHC-I molecules containing a broad diversity of oligosaccharides attachments and may be 
responsible for TAPBPR interacting with MHC-I further along the secretory pathway, as 
compared to tapasin (Figure 1). That being said, tapasin appears to have “first dibs” at 
glycosylated MHC-I. Thus, when the Glc1Man9GlcNAc2 moiety is attached to MHC-I, the 
tapasin/calreticulin/ERp57 complex has greater accessibility to MHC-I than TAPBPR. These 
findings are consistent with the notion that MHC-I initially load peptides in the PLC, which 
subsequently undergo TAPBPR-mediated peptide selection (Figure 1).    
 
TAPBPR influences MHC-I recycling 
In 2011, UDP-glucose:glycoprotein glucosyltransferase (UGT1) was shown to be involved in 
MHC-I quantity control and optimal peptide selection [30,31]. By reconstituting the 
Glc1Man9GlcNAc2 moiety on MHC-I loaded with suboptimal peptides, UGT1 promotes 
recognition of these molecules by calreticulin, consequently causing their re-engagement by 
the PLC. Subsequent experiments demonstrated that TAPBPR can act as a bridge between 
UGT1 and MHC-I molecules, which are potentially peptide receptive [32] (Figure 1). Thus, 
in addition to directly functioning as a peptide editor [13,14], TAPBPR plays an additional 
role in shaping the MHC-I immunopeptidome, by recycling sub-optimally loaded MHC-I 
molecules back to the PLC [32](Figure 1). As the TAPBPR:UGT1 complex is involved in 
modifying the glycan attached to MHC-I, this may explain why the interaction of TAPBPR 
with MHC-I occurs in a glycan-independent manner.  
 
What else is TAPBPR capable of doing? 
Through its interaction with UGT1, TAPBPR is able to facilitate the re-glucosylation of 
MHC-I [32]. This raises the question of whether TAPBPR could adopt alternative functions 
through interactions with additional co-factors. Furthermore, despite current research having 
predominately focused on the effect of TAPBPR on classical MHC-I, could TAPBPR serve 
as a chaperone for other ligands as well, for example non-classical MHC-I or MHC-I-related 
molecules? Naturally, there is also speculation regarding whether TAPBPR could be involved 
in MHC-I cross-presentation.  
 
The Outs of TAPBPR: TAPBPR is capable of functioning on plasma membrane 
expressed MHC-I 
Although TAPBPR usually resides intracellularly, we recently discovered that it can promote 
peptide exchange on cell surface-expressed MHC-I molecules [33]. By either over-expressing 
TAPBPR in cells (which results in a low proportion of TAPBPR leaking to the plasma 
membrane) or by adding recombinant TAPBPR exogenously onto cells, we revealed that 
TAPBPR could efficiently promote exogenous peptide loading directly onto surface 
expressed MHC-I [33](Figure 2). The ability of TAPBPR to function on surface-expressed 
MHC-I is consistent with other previously discovered properties of TAPBPR, including its 
binding to MHC-I in a glycan independent manner [24] and its ability to mediate peptide 
editing in the absence of other cofactors [13,14]. This discovery has led to a number of 
interesting developments and opportunities.   
   
New assays to explore TAPBPR function 
The ability of TAPBPR promote peptide exchange on plasma membrane expressed MHC-I 
has permitted the development of new assays to explore TAPBPR-mediated peptide editing. 
Prior to this, the only other available assay relied on assessing the effect of the luminal 
domain of TAPBPR on recombinant MHC-I refolds, using fluorescence polarization 
measurements [13,14]. This system was based on the pre-existing assay designed by Chen & 
Bouvier for tapasin [6]. From a biological perspective, the new experimental systems offer 
several advantages, as the MHC-I are in their naturally occurring transmembrane 
conformations, thus presenting a wide repertoire of peptides (albeit those which have passed 
through quality control mechanisms), containing a glycan (although a more mature 
oligosaccharide than would be found in the ER/Golgi) and abiding by the natural restrictions 
imposed by a cellular membrane. From a practical point of view, these assays represent high-
throughput tools for measuring TAPBPR-mediated peptide editing. They rely on the cellular 
machinery to express, fold and load membrane bound MHC-I molecules and thus circumvent 
the need to perform laborious refolding reactions with recombinant MHC-I expressed in 
bacteria. 
 
These newly established assays enabled us to explore whether the K22-D35 loop of TAPBPR 
was involved in mediating peptide exchange [21] as well as to determine which MHC-I 
allotypes are subjected to TAPBPR-mediated peptide editing [34]. Our findings suggest that 
TAPBPR displays a clear functional preference for HLA-A molecules, particularly for 
members of the A2 and A24 superfamilies, over HLA-B and -C molecules. Furthermore, this 
work revealed that molecular features of the HLA-A F pocket, specifically residues H114 and 
Y116, drive the propensity of MHC-I to undergo TAPBPR-mediated peptide exchange. The 
development of new systems to explore peptide selection on MHC-I widens our scope of 
experimentation which will ultimately lead to a better understanding of the processes 
involved.   
 
Potential use in Immunotherapy 
Intriguingly, recombinant TAPBPR can be used to decorate cells with antigenic peptides, 
including viral peptides and neo-epitopes [33] (Figure 2). Once loaded onto MHC-I, these 
peptides also appear to be available for recognition by antigen-specific CD8+ T cells [33], 
providing promising  translational opportunities for using TAPBPR to increase the 
immunogenicity of tumours. A key issue currently faced regarding the efficiency of 
immunotherapies is the low immunogenicity of tumours [35]. Recent discoveries suggest that 
even tumours displaying highly immunogenic peptides can avoid immune detection provided 
that only a small fraction of the tumour cells present the antigen [36]. Therefore, it will be 
interesting to explore whether the function of TAPBPR can be utilized in vivo to load 
immunogenic peptides of choice specifically onto tumours to increase the percentage of cells 
within a tumour that CTLs can detect and destroy, therefore turning immunologically ‘cold’ 
tumours into ‘hot’ tumours.   
 
Concluding remarks 
The discovery that TAPBPR can facilitate peptide exchange on cell surface expressed MHC-
I, if given access to the plasma membrane, raises queries regarding in which cellular 
localization TAPBPR naturally assists in peptide selection. While TAPBPR is present in the 
ER and Golgi, its fate post medial-Golgi remains largely enigmatic. While it does not appear 
to be present on the plasma membrane when expressed at physiological levels, it remains 
undetermined whether it localizes into the endosomal system. With its ability to dissociate 
high-affinity peptides from mature MHC-I, representative of MHC-I found in recycling 
endosomes, there is speculation whether TAPBPR may help facilitate MHC-I cross-
presentation by increasing the efficiency of peptide exchange, as occurs on MHC class II 
molecules via HLA-DM [37]. 
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Figure 1 – The Ins of TAPBPR: Its natural role within an intracellular environment. 
Within the PLC, tapasin assists in loading peptides onto MHC-I. These MHC-I may then 
either be transported through the Golgi for presentation on the cell surface or undergo 
TAPBPR-mediated peptide editing. If peptide editing occurs in the absence of a suitable 
incoming peptide, the MHC-I may become peptide-receptive.  UGT1 associated with 
TAPBPR can reglucosylate MHC-I, a modification which restores their recognition with 
calreticulin and recycling to the peptide loading complex.         
 
Figure 2 - The Outs of TAPBPR: TAPBPR is capable of functioning on plasma 
membrane expressed MHC-I. 
(A) When TAPBPR is over-expressed in mammalian cells by transduction or transfection, a 
small proportion of TAPBPR traffics to the plasma membrane. Due to its ability to interact 
with MHC-I in a glycan-independent manner, TAPBPR is capable of binding to, and 
performing peptide editing on, cell surface expressed MHC-I.  In the presence of high affinity 
peptides, including those derived from viruses or tumour-antigens, TAPBPR can efficiently 
promote exogenous peptide loading directly into plasma membrane expressed MHC-I.  (B) 
Treatment of mammalian cells with recombinant TAPBPR can also be used to promote 
exogenous peptide loading directly on plasma membrane expressed MHC-I.    
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